SCHEMBL1759513

SCHEMBL1759513

COc1ccccc1[CH]CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 6/20 0.53
TFEB P19484 1/20 0.52
KDM4E B2RXH2 2/20 0.50
TRPA1 O75762 1/20 0.50
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA12 O43570 1/20 0.48
CA4 P22748 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PLIN1 O60240 1/20 0.47
POLB P06746 1/20 0.47
PLIN5 Q00G26 1/20 0.47
ABHD5 Q8WTS1 1/20 0.47
GRIN2D O15399 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157682 0.83 NFE2L2 (0.53) NFE2L2TFEBKDM4ETRPA1CA1
SCHEMBL27751564 0.81 NFE2L2 (0.52) NFE2L2TFEBKDM4ETRPA1CA1
SCHEMBL2321858 0.80 NFE2L2 (0.59) NFE2L2TFEBKDM4ETRPA1MAPT
SCHEMBL2321861 0.80 NFE2L2 (0.59) NFE2L2TFEBKDM4ETRPA1MAPT
SCHEMBL12749162 0.80 NFE2L2 (0.59) NFE2L2TFEBKDM4ETRPA1MAPT
SCHEMBL29965840 0.80 NFE2L2 (0.59) NFE2L2TFEBKDM4ETRPA1MAPT
SCHEMBL240090 0.80 CA1 (0.60) NFE2L2TFEBKDM4ETRPA1CA1
SCHEMBL8879885 0.79 NFE2L2 (0.53) NFE2L2TFEBKDM4ETRPA1CA1
SCHEMBL28020798 0.79 NFE2L2 (0.50) NFE2L2TFEBKDM4ETRPA1CA1
SCHEMBL6158467 0.78 NFE2L2 (0.48) NFE2L2TFEBKDM4ETRPA1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765728-B2 [1,5]-diazocin derivatives MELLITECH (FR) 2014-07-01 US disclosed
EP-2501685-A1 [1,5]-DIAZOCIN DERIVATIVES Mellitech (FR) 2012-09-26 EP disclosed
US-20120225892-A1 [1,5]-Diazocin Derivatives MELLITECH (FR) 2012-09-06 US disclosed
WO-2011058193-A1 [1,5]-DIAZOCIN DERIVATIVES MELLITECH (FR) 2011-05-19 WO disclosed
CN-1024797-C Indole derivatives OTSUKA CHEMICAL CO LTD (JP) 1994-06-01 CN disclosed
CN-1049155-A INDOLE DERIVATIVES OTSUKA CHEMICAL CO LTD (JP) 1991-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225892-A1 [1,5]-Diazocin Derivatives IAPP, INSR, GLP1R NFE2L2 1294/4885TFEB 928/4885KDM4E 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.